Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
jaktinib
- Development stage
- Phase 3
- Lead developer
- Suzhou Zelgen Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Jaktinib is a novel small molecule inhibitor targeting Janus kinases (JAK1, JAK2, JAK3, TYK2) and activin A receptor type 1 (ACVR1). It blocks the JAK-STAT signaling pathway by inhibiting these kinases and thereby modulates immune responses and cytokine signaling. Additionally, inhibition of ACVR1 reduces hepcidin transcription to improve iron metabolism and anemia in myelofibrosis patients. Developed as a first-in-class drug in China for intermediate- or high-risk myelofibrosis (MF), it has also entered clinical trials for other indications such as alopecia areata, atopic dermatitis, psoriasis, and ankylosing spondylitis[2][3][4][6].
- Brand names
- jaktinib
- Other names
- 盐酸杰克替尼盐酸吉卡昔替尼Jaktinib hydrochloride
02
Targets
ACVR1 (Activin receptor type I)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)JAK3 (Janus kinase 3)TYK2 (Tyrosine kinase 2)TNK2 (Activated Cdc42-associated kinase 1)
Beyond the preview
Go deeper on jaktinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on jaktinib.